

## Special Issue

# When Vaccinations are Challenging: From Immune Diseases to Hypersensitivity Reactions

### Message from the Guest Editor

Although vaccines have been part of physicians' practice for many years and represent the most successful prevention strategy for communicable diseases, some challenges still characterize their daily use and applicability. In fact, vaccines have been recently proposed as part of the management of some peculiar conditions, such as immune diseases, particularly immunodeficiency, chronic respiratory diseases or bronchiectasis, and autoimmune diseases treated with immunosuppressant drugs. The expected outcomes, as well as their use in specific phenotypes, have not been completely clarified. Further, risk assessment, prevention, and management of hypersensitivity reactions to vaccines still present some controversial aspects. This *Vaccines* Special Issue aims at addressing the above-mentioned challenges and unmet needs through reviews and research contributions, including original articles and case series/reports.

### Guest Editor

Dr. Marco Caminati

Department of Medicine, University of Verona, Verona University Hospital, 37134 Verona, Italy

### Deadline for manuscript submissions

closed (31 May 2021)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/si/41394](https://mdpi.com/si/41394)

*Vaccines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).